Journal of Immunotherapy and Precision Oncology

Trastuzumab Deruxtecan-Associated Pneumonitis in Non-Breast Solid Tumors: A Retrospective Cohort Study ↗

Abdelrahman M. Attia, Jose Carlos Tuesta Delgado, Alexia Dayan Lecaros Zavalla, Kevin Bernal Medina et al.

Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report ↗

Marina Crespo-Cruz, Manuel Rodriguez-Justo, Adam Humphries, Andrew Plumb et al.

ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6 ↗

Atlal Abusanad

Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study ↗

Mohammad Aldawoud, Fatima Faqihi, Najd Algazlan, Marwa Alharbi et al.

Navigating Complexity in the Precision Oncology Clinic: Pharmacists’ Central Role in Drug Selection, Acquisition, and Dosing in a Real-World Clinic ↗

Justin Grahl, Roberto Ferrusquia, Megan Mills, Rachel Schneider et al.

Beyond Visibility: Social Media, Trust, and Responsibility in Oncology ↗

Joud Hajjar, Mark A. Lewis

The Double-Edged Role of Social Media in Modern Healthcare: Awareness, Impact, and Misinformation ↗

Jibran Ahmed, Atlal Abusanad, Gilberto Morgan

Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions ↗

Radiya Almosa, Megan Macalalad Mendoza, Tin-Yun Tang, Bettzy Stephen et al.

SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review ↗

Sarah Hendee, Gerald Falchook

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer ↗

Elias A. Castro, Yash C. Jani, Mehmet A. Bilen

Abstracts Presented at the 2026 Precision Oncology Saudi Summit: February 12–14, 2026, Madinah, Saudi Arabia ↗

Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond ↗

Soon Khai Low, Yu Fujiwara, Daisuke Nishizaki, Shumei Kato et al.

Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA ↗

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies ↗

Umut Dişel, Shumei Kato, Aditya Shreenivas, Ayca Ersen Danyeli et al.

Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer ↗

Muhammad Rizwan Khawaja, Gayle Jameson, Derek Cridebring, Patricia Shannon et al.

AXL Inhibitors in Oncology Clinical Trials: A Review ↗

Ethan Quach, Farahnoz Sanginova, Anish Cheruku, Sophia Stack et al.

Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study ↗

Khanh Toan Nguyen, Thi Huong Pham, Van Lam Ngo, Thi Thuy My Nguyen et al.

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration ↗

Lee S. Rosen, Christian Ottensmeier, Maria Hawkins, Aung Naing et al.

Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma ↗

Brenda Chahla, Bettzy Stephen, Juhee Song, Vania Balderrama-Brondani et al.

Characterizing Inquiries About Novel Cancer Therapies: Findings from the National Cancer Institute’s Cancer Information Service ↗

Robin C. Vanderpool, Laura Dwyer, Diane Ng, Beth Slotman et al.